Recently, the National Intellectual Property Administration announced the winners of the 25th China Patent Awards. Jiuzhou Pharma won the China Patent Excellence Award for its invention patent, "Asymmetric Hydrogenation Reaction of α-Keto Acid Compounds" (Patent No.: ZL201410468805.9). This follows last year’s achievement when Jiuzhou Pharma's "Halogenated S-(Perfluoroalkyl)-Dibenzothiophene Salt and Its Preparation Method" was awarded the 24th China Patent Excellence Award, marking another breakthrough for Jiuzhou Pharma in the field of intellectual property.

The China Patent Award is an authoritative award jointly organized by the National Intellectual Property Administration and the World Intellectual Property Organization (WIPO). It is the only government award in China that recognizes granted patent inventions and creations, representing the highest honor in the field of Chinese patents.

The awarded patent "Asymmetric Hydrogenation Reaction of α-Keto Acid Compounds" focuses on the direct catalysis of asymmetric hydrogenation of α-keto acid compounds using metal iridium chiral helical ligand complexes. This technology has successfully filled the technical gap in the asymmetric hydrogenation of α-keto acid compounds by metal-ligand complexes, offering significant advantages such as reduced catalyst usage, excellent catalytic efficiency, and outstanding stereoselectivity. It opens a new path for the synthesis of drugs and natural products containing α-hydroxy acid chiral building blocks. The resulting chiral α-hydroxy acid compounds, as key intermediates in natural products and pharmaceuticals, demonstrate enormous potential in pharmaceutical, chemical, and related industries.

More importantly, this patented technology has strongly supported the journey of the first domestically produced Class 1 anti-lung cancer drug from research and development to commercialization. With the help of this technology, the cost of chiral intermediates has been reduced by more than 50%, significantly improving the accessibility of anti-tumor drugs and allowing more patients worldwide to benefit. Additionally, this technology plays a crucial role in the design and development of new molecules for innovative drugs such as anti-tumor and anti-infection treatments, effectively promoting the high-quality development of the pharmaceutical manufacturing industry and generating significant social benefits.

This award is not only a strong recognition of Jiuzhou Pharma's technological innovation capabilities but also a full acknowledgment of the company's relentless efforts in intellectual property creation, protection, and utilization. Over the years, Jiuzhou Pharma has always regarded intellectual property as a core driving force for the company's development, continuously increasing investment in research and development, and focusing on independent innovation. As of 2024, the company has accumulated 310 international and domestic patents, forming a strong technological barrier and market competitiveness.

Looking to the future, Jiuzhou Pharma will continue to improve its intellectual property management system, constantly explore and break through core technologies, and make every effort to cultivate high-value patents. At the same time, the company will further strengthen the protection and conversion of intellectual property, driving the enterprise toward high-quality, sustainable development and injecting continuous vitality into the innovative development of the pharmaceutical industry.

Recently, the National Intellectual Property Administration announced the winners of the 25th China Patent Awards. Jiuzhou Pharma won the China Patent Excellence Award for its invention patent, "Asymmetric Hydrogenation Reaction of α-Keto Acid Compounds" (Patent No.: ZL201410468805.9). This follows last year’s achievement when Jiuzhou Pharma's "Halogenated S-(Perfluoroalkyl)-Dibenzothiophene Salt and Its Preparation Method" was awarded the 24th China Patent Excellence Award, marking another breakthrough for Jiuzhou Pharma in the field of intellectual property.

The China Patent Award is an authoritative award jointly organized by the National Intellectual Property Administration and the World Intellectual Property Organization (WIPO). It is the only government award in China that recognizes granted patent inventions and creations, representing the highest honor in the field of Chinese patents.

The awarded patent "Asymmetric Hydrogenation Reaction of α-Keto Acid Compounds" focuses on the direct catalysis of asymmetric hydrogenation of α-keto acid compounds using metal iridium chiral helical ligand complexes. This technology has successfully filled the technical gap in the asymmetric hydrogenation of α-keto acid compounds by metal-ligand complexes, offering significant advantages such as reduced catalyst usage, excellent catalytic efficiency, and outstanding stereoselectivity. It opens a new path for the synthesis of drugs and natural products containing α-hydroxy acid chiral building blocks. The resulting chiral α-hydroxy acid compounds, as key intermediates in natural products and pharmaceuticals, demonstrate enormous potential in pharmaceutical, chemical, and related industries.

More importantly, this patented technology has strongly supported the journey of the first domestically produced Class 1 anti-lung cancer drug from research and development to commercialization. With the help of this technology, the cost of chiral intermediates has been reduced by more than 50%, significantly improving the accessibility of anti-tumor drugs and allowing more patients worldwide to benefit. Additionally, this technology plays a crucial role in the design and development of new molecules for innovative drugs such as anti-tumor and anti-infection treatments, effectively promoting the high-quality development of the pharmaceutical manufacturing industry and generating significant social benefits.

This award is not only a strong recognition of Jiuzhou Pharma's technological innovation capabilities but also a full acknowledgment of the company's relentless efforts in intellectual property creation, protection, and utilization. Over the years, Jiuzhou Pharma has always regarded intellectual property as a core driving force for the company's development, continuously increasing investment in research and development, and focusing on independent innovation. As of 2024, the company has accumulated 310 international and domestic patents, forming a strong technological barrier and market competitiveness.

Looking to the future, Jiuzhou Pharma will continue to improve its intellectual property management system, constantly explore and break through core technologies, and make every effort to cultivate high-value patents. At the same time, the company will further strengthen the protection and conversion of intellectual property, driving the enterprise toward high-quality, sustainable development and injecting continuous vitality into the innovative development of the pharmaceutical industry.

Recently, the National Intellectual Property Administration announced the winners of the 25th China Patent Awards. Jiuzhou Pharma won the China Patent Excellence Award for its invention patent, "Asymmetric Hydrogenation Reaction of α-Keto Acid Compounds" (Patent No.: ZL201410468805.9). This follows last year’s achievement when Jiuzhou Pharma's "Halogenated S-(Perfluoroalkyl)-Dibenzothiophene Salt and Its Preparation Method" was awarded the 24th China Patent Excellence Award, marking another breakthrough for Jiuzhou Pharma in the field of intellectual property.

The China Patent Award is an authoritative award jointly organized by the National Intellectual Property Administration and the World Intellectual Property Organization (WIPO). It is the only government award in China that recognizes granted patent inventions and creations, representing the highest honor in the field of Chinese patents.

The awarded patent "Asymmetric Hydrogenation Reaction of α-Keto Acid Compounds" focuses on the direct catalysis of asymmetric hydrogenation of α-keto acid compounds using metal iridium chiral helical ligand complexes. This technology has successfully filled the technical gap in the asymmetric hydrogenation of α-keto acid compounds by metal-ligand complexes, offering significant advantages such as reduced catalyst usage, excellent catalytic efficiency, and outstanding stereoselectivity. It opens a new path for the synthesis of drugs and natural products containing α-hydroxy acid chiral building blocks. The resulting chiral α-hydroxy acid compounds, as key intermediates in natural products and pharmaceuticals, demonstrate enormous potential in pharmaceutical, chemical, and related industries.

More importantly, this patented technology has strongly supported the journey of the first domestically produced Class 1 anti-lung cancer drug from research and development to commercialization. With the help of this technology, the cost of chiral intermediates has been reduced by more than 50%, significantly improving the accessibility of anti-tumor drugs and allowing more patients worldwide to benefit. Additionally, this technology plays a crucial role in the design and development of new molecules for innovative drugs such as anti-tumor and anti-infection treatments, effectively promoting the high-quality development of the pharmaceutical manufacturing industry and generating significant social benefits.

This award is not only a strong recognition of Jiuzhou Pharma's technological innovation capabilities but also a full acknowledgment of the company's relentless efforts in intellectual property creation, protection, and utilization. Over the years, Jiuzhou Pharma has always regarded intellectual property as a core driving force for the company's development, continuously increasing investment in research and development, and focusing on independent innovation. As of 2024, the company has accumulated 310 international and domestic patents, forming a strong technological barrier and market competitiveness.

Looking to the future, Jiuzhou Pharma will continue to improve its intellectual property management system, constantly explore and break through core technologies, and make every effort to cultivate high-value patents. At the same time, the company will further strengthen the protection and conversion of intellectual property, driving the enterprise toward high-quality, sustainable development and injecting continuous vitality into the innovative development of the pharmaceutical industry.